【摘要】 目的:探讨咳喘宁胶囊对实验性慢性支气管炎治疗作用的内在机制。方法:采用改良烟熏法复制大鼠慢性支气管炎模型,实验分组为模型组、咳高组、咳低组、桂龙组,并设不加处理的正常对照组。以高、低剂量咳喘宁和桂龙咳喘宁进行干预,用放免法测定各组大鼠血清、肺组织及支气管肺泡灌洗液（BALF）中血栓素B₂（TXB₂）和6-酮-前列腺素F_1α(6-keto-PGF_1α)的含量。结果:模型组大鼠血清、肺组织及BALF中TXB₂和6-keto-PGF_1α及其比值均较正常组明显升高（P<0.01）;与模型组相比较,咳高组和桂龙组血清、肺组织及BALF中TXB₂和6-keto-PGF_1α含量及其比值均有明显降低（P<0.05或P<0.01）,而咳低组无明显差异;咳高组血清、肺组织及BALF中TXB₂和6-keto-PGF_1α含量显著低于桂龙组（P<0.05或P<0.01）。结论:咳喘宁胶囊可通过降低TXB₂和6-keto-PGF_1α含量发挥治疗作用。更多还原

【Abstract】 To make research on the internal mechanism of treating experimental chronic bronchitis with Kechuanning Capsule. We duplicated the animal model of chronic bronchitis with refined smoking-fumigated method, the rats were allocated to model group, high dose group, low dose group , Guilong group and normal control group that didn t treated. Made intervention with high and low dose of Kechuanning as well as Guilong Kechuanning (another medicine of the similar kind) and determined the TXB2 &6-keto-PGF1α contents in the blood serum, lung tissue and BALF of each group with radiom-munoassay. The TXB2 &6-keto-PGF1α content as well as its radio in the blood serum, lung tissue and BALF of the model group were significantly improved than the normal group ( P < 0.01) . Compared with the model group, the TXB2 &6-ke-to-PGF1α content as well as its ratio in the blood serum, lung tissue and BALF of the high dose group and Guilong group were significantly reduced (P <0.05 or P < 0.01) ; while the low dose group hadn’t significant difference.The TXB2 &6-keto-PGF1α content as well as radio in the blood, lung tissue and BALF of the high dose group were significantly lower than that of the Guilong group ( P < 0.05 or P < 0.01). Kechuanning capsules could produce therapeutical effect by decrease the TXB2 &6-keto-PGF1αcontent as well as its ratio.更多还原